Field-triage and ED bypass were feasible means of reducing treatment delay in patients with suspected STEMI and resulted in smaller infarct size in early presenters and a trend towards a reduction in mortality.
Giant magnetoresistance (GMR) at 300 K and 5.5 T with ΔR/R(0)=74% was observed in single crystals of La0.65(PbCa)0.35MnO3. The maximum GMR occurs exactly at the ferromagnetic–paramagnetic phase transition temperature (Tc). For T<Tc, the R(T) curve is closely related to the M(T) curve. A sign change in the curvatures of R(H) curves below and above Tc has been observed, indicating that two different mechanisms are responsible for the magnetic scatterings of the carriers in two separate temperature regions.
Sr 3 CuPt x Ir 1Ϫx O 6 has been cited as an example of a one-dimensional quantum spin chain with competing ferromagnetic and antiferromagnetic interactions. We have measured the ac susceptibility of Sr 3 CuPt x Ir 1Ϫx O 6 with xϭ0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, and 0.7, in magnetic fields of 0-60 kOe, and at temperatures down to 0.275 K. Our data show that the xϭ0 endpoint, Sr 3 CuIrO 6 , exhibits long-range ferromagnetic order at T ϭ20.1 K, contrary to results from dc susceptibility studies which indicated that it remained a one-dimensional ferromagnet to below 4 K. When platinum is substituted for iridium, antiferromagnetic couplings are introduced, and the susceptibility shows a diminishing signature of the three-dimensional ferromagnetic transition. Furthermore, the low-temperature susceptibility exhibits peaks which appear and evolve as x is increased. These results lead to a rich phase diagram in temperature and Pt concentration space. We find that the behavior of Sr 3 CuPt x Ir 1Ϫx O 6 cannot be simply described by the random quantum spin chain theories that were developed, in part, to address this system.
Single crystals of C&o were doped with alkali metal (K and Rb), characterized, and measured magnetically in fields up to 5 T. Detailed experiments show the samples to be of high quality with superconducting transition widths on the order of 1 K. Data on the field and temperature dependences of the critical current density J& and Hc& are presented. We find that while the general behavior is similar to that of powder specimens, there are significant differences when comparing magnitudes. We attribute these differences to the fact that powder samples have much more surface area per volume than single crystals which can affect the determination of superconducting parameters. The critical current density also shows clear differences when compared to polycrystalline samples. In addition, comparisons between K3C6o and Rb3C6o indicate that defects may be more prevalent in the latter compound due to more sensitive synthesis requirements.
Europium fullerides
Eu
x
C60 (x = 1−6) were
prepared by metal ammonia solution synthesis.
The products were investigated by X-ray powder diffraction,
optical spectroscopy, FTIR, mass
spectrometry, and magnetic susceptibility. All products were
amorphous by powder X-ray
diffraction and were free of ammonia as determined by mass
spectrometry. Products
prepared with x = 1, 2, 3 showed the presence of unreacted
C60 in the optical spectra, FTIR
spectra, and the powder diffraction pattern. FTIR spectra of the
Eu
x
C60 prepared with x
=
3 show red-shifted frequencies of F1u(4) at 1399 and
1352 (1411) cm-1, suggesting the
presence
of C60
- and
C60
6-. FTIR spectra of
Eu
x
C60 samples prepared with
x = 4, 5, 6 also show red-shifted frequencies and are discussed in detail. Magnetic
susceptibility measurements show
Curie−Weiss behavior above 50 K with experimental magnetic moments of
6.6 (1), 6.9 (1),
and 5.9 (1) μB/Eu for x = 3, 4, 5 samples,
respectively.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.